The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...

Three GLP-1 drugs are best at helping obese and overweight people drop weight, including one that hasn’t yet been ap ...

Metsera has linked its GLP-1 drug candidate to weight loss of up to 11.3% after 12 weeks, encouraging the biotech to use some ...

Zepbound led to an average weight loss of 20.2 percent compared to ... while Wegovy’s established cardiovascular data makes it a strong choice for heart health considerations,” notes Dr ...

The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...

In a recent episode of the global health and wellness show Bloom, host Gayle Guyardo welcomed Dr. Bharti Shetye, MD, MFOMA, a ...

Americans are getting slimmer. The rise of GLP-1 medications has transformed the way Americans lose weight, and the data supports that: ...

Eli Lilly has asked to join in opposing a lawsuit brought by compounding pharmacies against the U.S. Food and Drug ...

Study finds GLP-1 medications such as Ozempic could result in cuts to grocery spending and reductions in spending at ...

Given Wegovy’s success and record-high sales, a wave of investments has gone into the obesity space over the last couple of ...

Eli Lilly’s Zepbound drug holds potential to dominate the global obesity market due to its superior efficacy and strategic ...

The Indiana Family and Social Service Administration’s Office of Medicaid Policy and Planning estimates that 5% to 20% of ...